← Back to Search

Other

A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology

Phase 2
Waitlist Available
Research Sponsored by Cyclerion Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from first dose of study treatment through ~14 (±4) days after the final dose

Summary

This trial is testing CY6463, a new drug, in people aged 60+ with Alzheimer's and cardiovascular issues. The drug aims to improve brain function by enhancing a key signaling pathway. Participants will take the drug regularly for a few months. CY6463 has shown potential in reducing inflammation and improving brain function in neurodegenerative diseases.

Eligible Conditions
  • Mixed Dementia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from first dose of study treatment through ~14 (±4) days after the final dose
This trial's timeline: 3 weeks for screening, Varies for treatment, and from first dose of study treatment through ~14 (±4) days after the final dose for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of Treatment-emergent Adverse Events (TEAEs) From Study Drug Initiation Through Follow-up

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: CY6463Experimental Treatment1 Intervention
CY6463 once daily (QD) for approximately 87 sequential days.
Group II: PlaceboPlacebo Group1 Intervention
Placebo QD for approximately 87 sequential days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CY6463
2021
Completed Phase 1
~50

Find a Location

Who is running the clinical trial?

Cyclerion TherapeuticsLead Sponsor
17 Previous Clinical Trials
885 Total Patients Enrolled
Tisento TherapeuticsLead Sponsor
5 Previous Clinical Trials
234 Total Patients Enrolled
Study DirectorStudy DirectorTisento Therapeutics
1,281 Previous Clinical Trials
500,490 Total Patients Enrolled
Chad Glassar, PharmDStudy DirectorCyclerion Therapeutics
Chad Glasser, PharmDStudy DirectorCyclerion Therapeutics
3 Previous Clinical Trials
142 Total Patients Enrolled
~3 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top